Taysha Gene Therapies’ (TSHA) “Overweight” Rating Reiterated at Cantor Fitzgerald

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research report issued on Tuesday,Benzinga reports. They currently have a $7.00 target price on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 216.74% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on the company. Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, August 13th. Canaccord Genuity Group reduced their price target on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. Finally, Needham & Company LLC restated a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies has a consensus rating of “Buy” and an average price target of $6.38.

Taysha Gene Therapies Trading Down 7.5 %

NASDAQ TSHA opened at $2.21 on Tuesday. The company has a current ratio of 5.22, a quick ratio of 5.22 and a debt-to-equity ratio of 0.35. The company has a fifty day simple moving average of $1.97 and a two-hundred day simple moving average of $2.39. Taysha Gene Therapies has a 12-month low of $1.19 and a 12-month high of $4.32. The stock has a market cap of $452.92 million, a P/E ratio of -11.15 and a beta of 0.44.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. The company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $3.62 million. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. During the same quarter in the prior year, the company earned ($0.38) EPS. On average, analysts forecast that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Creative Planning acquired a new position in Taysha Gene Therapies in the third quarter valued at approximately $28,000. Principal Financial Group Inc. acquired a new stake in Taysha Gene Therapies during the second quarter worth approximately $48,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after buying an additional 17,446 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Taysha Gene Therapies in the 3rd quarter valued at $85,000. Finally, Scientech Research LLC purchased a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at $97,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.